Rapid Micro Biosystems (RPID)
NASDAQ:RPID
Want to see RPID full AI Analyst Report?
Top Page
Rapid Micro Biosystems
(NASDAQ:RPID)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▲(9.65% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance: large ongoing losses, heavy cash burn, and higher balance-sheet leverage. The earnings call adds some support via reaffirmed guidance, improving recurring revenue mix, and an outlined path to better margins, but execution/liquidity risks remain meaningful. Technically, the stock is still below key moving averages, and valuation is hard to assess due to negative earnings and no indicated dividend yield.
Positive Factors
Recurring revenue expansion
A rising recurring mix (consumables/services = 63% of revenue) improves revenue stability and predictability over multi-year instrument lifecycles. Durable consumables attach-rates convert installed systems into repeatable revenue and higher lifetime value, lowering reliance on one-time instrument sales.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow creates ongoing funding needs and dilutive or covenant-driven financing risk. Until operations generate positive cash, management must secure credit or equity, which constrains capital allocation and heightens execution sensitivity over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue expansion
A rising recurring mix (consumables/services = 63% of revenue) improves revenue stability and predictability over multi-year instrument lifecycles. Durable consumables attach-rates convert installed systems into repeatable revenue and higher lifetime value, lowering reliance on one-time instrument sales.
Read all positive factors
Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$93.82M
Dividend YieldN/A
Average Volume (3M)253.56K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth15.99%
EPS Growth-8.91%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.11
Shares Outstanding41,267,510
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit24.11
Enterprise Value/Ebitda-2.21
Forecast
1Y Price Target
$7.50Price Target Upside228.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$39.40M
Rapid Micro Biosystems Business Overview & Revenue Model
Company Description
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. ...
How the Company Makes Money
Rapid Micro Biosystems makes money primarily by selling its automated microbial detection platform and generating recurring revenue from ongoing consumables and services tied to the installed base. Key revenue streams include: (1) Product revenue ...
Rapid Micro Biosystems Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but improving picture: revenue, product/consumables growth, recurring revenue expansion, system placements, and a strategic MilliporeSigma partnership are meaningful positives and support long-term margin improvement. However, near-term challenges include low absolute gross margins, a widened net loss, elevated operating expenses, significant Q1 cash burn, and variability in service revenue tied to validation timing. Management reiterated full-year revenue guidance and outlined margin improvement expectations, but execution risk and liquidity depend on achieving planned cost reductions, converting the sales funnel (including MilliporeSigma-driven placements), and unlocking credit facility tranches.Positive Updates
Revenue Growth
Total revenue of $8.0M in Q1 2026, up 11% year-over-year (from $7.2M). Full-year 2026 revenue guidance reaffirmed at $37M to $41M.
Negative Updates
Low Absolute Gross Margin and Continued Negative Product Margin
Q1 total gross margin remained low at 5% and product margin, while improved, was still negative at -8% in the quarter. Company expects product margin to inflect positive beginning in Q2 but current absolute margins remain a near-term weakness.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $8.0M in Q1 2026, up 11% year-over-year (from $7.2M). Full-year 2026 revenue guidance reaffirmed at $37M to $41M.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 guidance of $37–$41 million in revenue and 30–38 Growth Direct system placements (with at least 25 validations expected in 2026), and guided Q2 revenue of at least $7.7 million including at least 4 system placements; they expect full‑year gross margin of ~20% with Q2 gross margin in the mid‑ to high‑teens and a Q4 exit in the mid‑20% range (product margin in the high single digits to low teens; service margin >40%). Full‑year operating expenses are guided to $48–52 million with total noncash expenses of $8 million (D&A ~$3M, stock‑based comp ~$5M; $7M of noncash in OpEx and $1M in cost of revenue), CapEx ~$2M, interest income ~$1M and interest expense ~$2M. For context, Q1 results included $8.0M revenue (+11% YoY), six system placements in the quarter (196 systems placed globally, 160 fully validated), product revenue $5.6M (+36%), service revenue $2.4M, recurring revenue $5.1M (63% of total, +28%), Q1 gross margin 5% ($0.4M), Q1 net loss $14.3M, $15M cash used in Q1, $23M ending cash and $25M remaining availability under the Trinity credit facility (two $10M tranches and a $5M lender option).Rapid Micro Biosystems Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.38M | 33.59M | 28.05M | 22.52M | 17.13M | 23.23M |
| Gross Profit | 4.26M | 7.61M | -109.00K | -5.49M | -8.54M | -7.74M |
| EBITDA | -46.59M | -44.14M | -46.56M | -53.46M | -60.38M | -45.70M |
| Net Income | -50.14M | -47.12M | -46.89M | -52.47M | -60.81M | -73.52M |
Balance Sheet | ||||||
| Total Assets | 62.36M | 74.85M | 98.17M | 143.45M | 190.65M | 241.17M |
| Cash, Cash Equivalents and Short-Term Investments | 22.95M | 38.30M | 50.73M | 92.05M | 108.65M | 193.50M |
| Total Debt | 23.71M | 23.87M | 6.17M | 7.35M | 7.97M | 0.00 |
| Total Liabilities | 41.97M | 41.65M | 22.82M | 25.46M | 26.48M | 20.19M |
| Stockholders Equity | 20.40M | 33.21M | 75.35M | 117.99M | 164.17M | 220.98M |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -31.91M | -45.52M | -46.93M | -65.29M | -58.18M |
| Operating Cash Flow | -36.18M | -31.06M | -44.15M | -45.08M | -58.55M | -54.96M |
| Investing Cash Flow | 12.24M | 14.33M | 36.66M | 42.15M | -93.47M | -13.29M |
| Financing Cash Flow | 18.76M | 19.77M | 203.00K | 149.00K | 693.00K | 216.75M |
Rapid Micro Biosystems Technical Analysis
Negative
2.28
Price Trends
2.34
Negative
3.14
Negative
3.20
Negative
Market Momentum
-0.12
Positive
37.27
Neutral
18.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Negative. The current price of 2.28 is below the 20-day moving average (MA) of 2.34, below the 50-day MA of 2.34, and below the 200-day MA of 3.20, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 37.27 is Neutral, neither overbought nor oversold. The STOCH value of 18.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPID.
Rapid Micro Biosystems Risk Analysis
Rapid Micro Biosystems disclosed 69 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapid Micro Biosystems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $273.68M | -3.92 | -59.10% | ― | 1.85% | 27.73% | |
52 Neutral | $147.91M | -3.06 | -101.28% | ― | 30.66% | 25.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $73.72M | 0.50 | -514.92% | ― | 1.12% | ― | |
46 Neutral | $217.28M | -2.11 | -370.21% | ― | 23.03% | 60.80% | |
45 Neutral | $93.82M | -1.81 | -131.52% | ― | 15.99% | -8.91% | |
44 Neutral | $65.47M | -0.99 | -82.79% | ― | 1.23% | 10.65% |
* Healthcare Sector Average
RPID
Rapid Micro Biosystems
2.05
-1.50
-42.25%
LUNG
Pulmonx
1.55
-1.54
-49.76%
LNSR
LENSAR
6.09
-7.49
-55.15%
HYPR
Hyperfine
1.49
0.83
125.76%
SGHT
Sight Sciences
5.03
1.59
46.22%
LUCD
Lucid Diagnostics
1.07
-0.45
-29.61%
Rapid Micro Biosystems Corporate Events
Business Operations and StrategyExecutive/Board Changes
Rapid Micro Biosystems Announces COO Transition and Consulting Role
Neutral
Mar 27, 2026
On March 23, 2026, Rapid Micro Biosystems announced that Chief Operating Officer John Wilson intends to depart the company effective April 10, 2026, citing a desire to spend more time with his family and with no disagreements regarding company ope...
Business Operations and StrategyFinancial Disclosures
Rapid Micro Biosystems Posts Record 2025 Results, Guides Higher
Positive
Mar 12, 2026
On March 12, 2026, Rapid Micro Biosystems reported record results for the fourth quarter and full year 2025, with Q4 revenue rising 37% year over year to $11.3 million and full-year revenue up 20% to $33.6 million, driven by increased product and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.